Evidence map›Paper›PMID 30972285›Full record

ArticleActa pharmaceutica Sinica. B2019

Transformative hyaluronic acid-based active targeting supramolecular nanoplatform improves long circulation and enhances cellular uptake in cancer therapy.

Lu Zhong, Lu Xu, Yanying Liu, Qingsong Li, Dongyang Zhao, Zhenbao Li, Huicong Zhang, Haotian Zhang, Qiming Kan, Yongjun Wang and 2 more

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Acta pharmaceutica Sinica. B, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers.

0numbers the graph read from it
0cells of the map it votes in
34citing papers in PubMed
5.3field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

34 citing papers in PubMed, 97 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Review
  7. Review
  8. Review
  9. Article
  10. Article
  11. Synthesis and characterization of GdScientific reports · 2023
    Article
  12. Article
  13. Article
  14. Review
  15. Article
  16. Article
  17. Article
  18. Review
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 1 institution in 1 country.

Lu ZhongDepartment of Pharmaceutics, Wuya College of Innovation, Shenyang Pharmaceutical University, Shenyang 110016, China.
Lu XuDepartment of Pharmaceutics, Wuya College of Innovation, Shenyang Pharmaceutical University, Shenyang 110016, China.
Yanying LiuDepartment of Pharmaceutics, Wuya College of Innovation, Shenyang Pharmaceutical University, Shenyang 110016, China.
Qingsong LiDepartment of Pharmaceutics, Wuya College of Innovation, Shenyang Pharmaceutical University, Shenyang 110016, China.
Dongyang ZhaoDepartment of Pharmaceutics, Wuya College of Innovation, Shenyang Pharmaceutical University, Shenyang 110016, China.
Zhenbao LiDepartment of Pharmaceutics, Wuya College of Innovation, Shenyang Pharmaceutical University, Shenyang 110016, China.
Huicong ZhangDepartment of Pharmaceutics, Wuya College of Innovation, Shenyang Pharmaceutical University, Shenyang 110016, China.
Haotian ZhangDepartment of Pharmacy, Shenyang Pharmaceutical University, Shenyang 110016, China.
Qiming KanDepartment of Pharmacy, Shenyang Pharmaceutical University, Shenyang 110016, China.
Yongjun WangDepartment of Pharmaceutics, Wuya College of Innovation, Shenyang Pharmaceutical University, Shenyang 110016, China.
Jin SunDepartment of Pharmaceutics, Wuya College of Innovation, Shenyang Pharmaceutical University, Shenyang 110016, China.
Zhonggui HeDepartment of Pharmaceutics, Wuya College of Innovation, Shenyang Pharmaceutical University, Shenyang 110016, China.
Shenyang Pharmaceutical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Hyaluronic acid (HA) is a natural ligand of tumor-targeted drug delivery systems (DDS) due to the relevant CD44 receptor overexpressed on tumor cell membranes. However, other HA receptors (HARE and LYVE-1) are also overexpressing in the reticuloendothelial system (RES). Therefore, polyethylene glycol (PEG) modification of HA-based DDS is necessary to reduce RES capture. Unfortunately, pegylation remarkably inhibits tumor cellular uptake and endosomal escapement, significantly compromising the

Indexed as

Active-targetingADA, 1-adamantane carboxylic acidAD-B-PEG, the pH-responsive adamantane-PEG conjugateAD-O-PEG, the non-pH sensitive adamantane-PEG conjugateAUC, area under the plasma concentration—time curveBenzoic imine linkageCancer therapyCLSM, confocal laser scanning microscopeDAPI, 2-(4-amidinophenyl)-6-indolecarbamidine dihydrochlorideDCC, N,N′-dicyclohexylcarbodiimideDCM, dichloromethaneDDS, drug delivery systemsDiR, 1,1′-dioctadecyltetramethyl indotricarbocyanine iodideDL, drug-loading contentDLS, dynamic light scatteringDMAP, 4-dimethylaminopyrideineDMEM, Dulbecco׳s modified Eagle׳s mediumDox·HCl, doxorubicin hydrochlorideDox/HCVBP, Dox-loaded hyaluronic acid-based transformable supramolecular nanoplatformDox/HCVOP, Dox-loaded hyaluronic acid-based untransformable supramolecular nanoplatformEDC, 1-ethyl-3-(3-dimethyalminopropl) carbodiimideEE, encapsulation efficiencyFBS, fetal bovine serumHA-CD, hydroxypropyl-β-cyclodextrin grafted hyaluronic acid polymerHA, hyaluronic acidHCBP, hydroxypropyl-β-cyclodextrin grafted hyaluronic acid polymer and pH-responsive adamantane-PEG conjugate inclusion complexHCPs, hydroxypropyl-β-cyclodextrin grafted hyaluronic acid polymer and adamantane-PEG conjugate inclusion complexesH&E, hematoxylin and eosinHEPES, 4-(2-hydroxyethyl)-1-piperazineethanesul-fonic acidHOBT, 1-hydroxybenzotriazoleHPCD, hydroxypropyl-β-cyclodextrinHyaluronic acidMW, molecular weightNatural ligandNPs, nanoparticlesPCC, Pearson׳s correlation coefficientPDI, polydispersity indexPEG dilemmapHe, the extracellular pHRES, reticuloendothelial systemRPMI-1640, Roswell Park Memorial Institute-1640Supramolecular nanoplat-formTHF, tetrahydrofuranTransformative nanoparti-clesTUNEL, terminal deoxynucleotidyl transferased dUTP nick end labelingVES, vitamin E succinate

Identifiers

PMID30972285
PMCPMC6437598
OpenAlexW2902459470

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.